Cellular Biomedicine Group, Inc. (CBMG) Analysts See $-0.52 EPS

August 9, 2018 - By Lisa Delgado

Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) LogoInvestors sentiment increased to 2.6 in Q1 2018. Its up 1.89, from 0.71 in 2017Q4. It improved, as 2 investors sold Cellular Biomedicine Group, Inc. shares while 3 reduced holdings. 8 funds opened positions while 5 raised stakes. 685,017 shares or 44.95% more from 472,598 shares in 2017Q4 were reported.
Northern Corp holds 37,980 shares or 0% of its portfolio. Goldman Sachs Group has 0% invested in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) for 52,843 shares. National Bank Of Mellon Corp reported 11,225 shares. State Street Corporation owns 11,329 shares for 0% of their portfolio. California Employees Retirement System holds 0% or 19,000 shares. Blackrock, a New York-based fund reported 89,615 shares. 15,238 were reported by Morgan Stanley. Meeder Asset holds 0% or 53 shares. Millennium Management Limited Liability Company, New York-based fund reported 105,101 shares. Deutsche Bancorp Ag has 0% invested in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) for 123 shares. Barclays Pcl invested in 0% or 1,600 shares. Dimensional Fund Advsr Lp accumulated 21,197 shares or 0% of the stock. West Oak Capital Ltd Liability holds 100 shares or 0% of its portfolio. 7 are owned by Bnp Paribas Arbitrage. The Pennsylvania-based Vanguard Grp has invested 0% in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG).

Since April 10, 2018, it had 0 insider purchases, and 1 sale for $450,832 activity.

Analysts expect Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) to report $-0.52 EPS on August, 14.They anticipate $0.09 EPS change or 20.93 % from last quarter’s $-0.43 EPS. After having $-0.51 EPS previously, Cellular Biomedicine Group, Inc.’s analysts see 1.96 % EPS growth. The stock increased 0.97% or $0.2 during the last trading session, reaching $20.8. About 14,141 shares traded. Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) has risen 210.91% since August 9, 2017 and is uptrending. It has outperformed by 198.34% the S&P500.

Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) Ratings Coverage

Among 2 analysts covering Cellular Biomedicine Group (NASDAQ:CBMG), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Cellular Biomedicine Group had 2 analyst reports since March 8, 2018 according to SRatingsIntel. The stock has “Buy” rating by FBR Capital on Thursday, March 8.

Cellular Biomedicine Group Inc., a biopharmaceutical company, develops treatments for cancerous and degenerative diseases in Greater China. The company has market cap of $353.73 million. It focuses on developing and marketing cell therapies to treat serious diseases, such as cancer, orthopedic, and various inflammatory diseases, as well as metabolic diseases. It currently has negative earnings. The firm develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; and tumor cell specific dendritic cell therapy.

More news for Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) were recently published by: Nasdaq.com, which released: “Cellular Biomedicine Group Reports Second Quarter and First Half 2018 Financial Results and Business Highlights” on August 08, 2018. Prnewswire.com‘s article titled: “Rise of Chronic Diseases Leads to Growing Investment in Stem Cell Research” and published on July 11, 2018 is yet another important article.

Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.